Explore › Finding
Finding adverse
Urinary tract infections were significantly more frequent in the onabotulinumtoxinA group than in the sacral neuromodulation group (35% vs 11%; risk difference, -23%; 95% CI, -33% to -13%; P < .001), with 39% of onabotulinumtoxinA participants who had a UTI experiencing multiple infections.
Effect size35% vs 11%; risk difference, -23%
CI95% CI, -33% to -13%
Follow-up6 months
ComparatorSacral neuromodulation (InterStim)
Effect summaryadverse; 35% vs 11%; risk difference, -23%; CI: 95% CI, -33% to -13%
Adverse eventsurinary tract infections 35%, multiple infections 39%

Connected entities

Interventions
OnabotulinumtoxinA 200 unit powder for solution for injection vial
Conditions
urgency urinary incontinence
Outcomes
Urinary tract infection

Source

PMC5399419
OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women A Randomized Clinical Trial
Read on PMC → · View in graph →